Bass, Berry & Sims member Shannon Wiley will present on an on-demand webinar for The American Health Law Association (AHLA), titled “Does TrumpRx Deliver? Evaluating Real Savings, Market Impact, and Unresolved Legal Questions.” Shannon, alongside co-speakers Brian Hoyt and Tiffanie McDowell, will provide a fact-based examination of the Trump administration’s direct-to-consumer prescription drug platform, including its structure, potential cost savings, and impact on consumers and the broader healthcare market. The program will also explore the U.S. Department of Health and Human Services Office of Inspector General’s January 2026 guidance on direct-to-consumer drug sales, highlighting key legal and compliance considerations, unresolved Anti-Kickback Statute questions, and implications for payers, health plans, and other healthcare stakeholders.
Learning Objectives Include:
- Learn TrumpRx works and whether it offers meaningful savings to consumers.
- Analyze the OIG’s January 2026 DTC guidance, including its gaps and unresolved legal questions.
- Evaluate TrumpRx’s implications for payers, plans, and the managed care landscape.
This on-demand CLE webinar will be released on May 27, 2026, and will be available for purchase for approximately one year after the recording date. For more information, please visit the AHLA website.